LEADER 01298cam0-22004571i-450- 001 990000774540403321 005 20160926152241.0 035 $a000077454 035 $aFED01000077454 035 $a(Aleph)000077454FED01 035 $a000077454 100 $a20020821d1988----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $aa-------001yy 200 1 $a<>problematica di architettura tecnica$ela prevenzione incendi$fBenito De Sivo, Renato Iovino, Giovanni Cito 210 $aNapoli$cCUEN$d1988 215 $a117 p.$cill.$d24 cm 610 0 $aArchitettura tecnica 610 0 $aIncendi 610 0 $aPrevenzione 610 0 $aEdifici$aIncendi$aPrevenzione 610 0 $aSicurezza Edilizia 676 $a628.922 676 $a693.82 676 $a628.9 700 1$aDe Sivo,$bBenito$0630 701 1$aCito,$bGiovanni$0631 701 1$aIovino,$bRenato$f<1943- >$0332892 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990000774540403321 952 $aTECN B 789$bINV.2544$fFARBC 952 $a13 P 11 18$b5603$fFINBC 952 $a08 C 279$b303$fDINED 952 $a13 43 15$b5602$fFINBC 959 $aFARBC 959 $aFINBC 959 $aDINED 996 $aProblematica di architettura tecnica$9349793 997 $aUNINA LEADER 02858nam 2200505 450 001 9910484814103321 005 20210320231253.0 010 $a981-15-8423-0 024 7 $a10.1007/978-981-15-8423-7 035 $a(CKB)4100000011645134 035 $a(DE-He213)978-981-15-8423-7 035 $a(MiAaPQ)EBC6422868 035 $a(PPN)252513207 035 $a(EXLCZ)994100000011645134 100 $a20210320d2021 uy 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aApplications of fdg pet in oncology $ebest clinical practice /$fedited by Hirofumi Fujii, Hiroyuki Nakamura, Seiei Yasuda 205 $a1st ed. 2021. 210 1$aSingapore :$cSpringer,$d[2021] 210 4$dİ2021 215 $a1 online resource (VII, 147 p. 61 illus., 55 illus. in color.) 311 $a981-15-8422-2 327 $a1 Overview.-2 Lung cancer.-3 Breast cancer -- 4 Head and neck cancer.-5 Gastrointestinal cancer including GIST -- 6 Pancreatic cancer -- 7 Urological cancer -- 8 Malignant bone and soft tissue tumors -- 9 Skin cancer including malignant melanoma -- 10 Malignant lymphoma. 330 $aThis book provides up-to-date guidance on the use of FDG PET to assess the biological activity and treatment response of a wide range of malignancies, including, for example, lung cancer, breast cancer, head and neck cancer, gastrointestinal cancer, and malignant lymphoma. In the era of precision medicine, numerous new anticancer agents, such as molecular targeted agents and immune checkpoint inhibitors, have been developed to improve outcomes in cancer patients. FDG PET plays a key role in evaluating the effects of these novel treatments because it can detect changes in the metabolic activity of tumors before any reduction in their size is visible on other imaging modalities. Accordingly, FDG PET is of prognostic as well as diagnostic value, and allows prompt changes in patient management. The book is written by expert clinicians from Japan, where the universal public health insurance system ensures that FDG PET is widely used in routine oncological practice and cancer screening. It represents an unrivaled and comprehensive resource that will be of value for all healthcare professionals in the field of clinical oncology. 606 $aCancer$xTomography 606 $aOncology 606 $aTomography, Emission 615 0$aCancer$xTomography. 615 0$aOncology. 615 0$aTomography, Emission. 676 $a660.05 702 $aFujii$b Hirofumi 702 $aNakamura$b Hiroyuki 702 $aYasuda$b Seiei 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910484814103321 996 $aApplications of FDG PET in Oncology$92585241 997 $aUNINA